ABIVAX SA (ABVX.PA) Fundamental Analysis & Valuation

EPA:ABVX • FR0012333284

Current stock price

96 EUR
-1.95 (-1.99%)
Last:

This ABVX.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ABVX.PA Profitability Analysis

1.1 Basic Checks

  • ABVX had negative earnings in the past year.
  • In the past year ABVX has reported a negative cash flow from operations.
  • In the past 5 years ABVX always reported negative net income.
  • In the past 5 years ABVX always reported negative operating cash flow.
ABVX.PA Yearly Net Income VS EBIT VS OCF VS FCFABVX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of ABVX (-280.92%) is worse than 95.06% of its industry peers.
Industry RankSector Rank
ROA -280.92%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ABVX.PA Yearly ROA, ROE, ROICABVX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ABVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVX.PA Yearly Profit, Operating, Gross MarginsABVX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ABVX.PA Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for ABVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABVX.PA Yearly Shares OutstandingABVX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABVX.PA Yearly Total Debt VS Total AssetsABVX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • ABVX has an Altman-Z score of 14.51. This indicates that ABVX is financially healthy and has little risk of bankruptcy at the moment.
  • ABVX has a better Altman-Z score (14.51) than 91.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 14.51
ROIC/WACCN/A
WACCN/A
ABVX.PA Yearly LT Debt VS Equity VS FCFABVX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 0.77 indicates that ABVX may have some problems paying its short term obligations.
  • ABVX's Current ratio of 0.77 is on the low side compared to the rest of the industry. ABVX is outperformed by 81.48% of its industry peers.
  • ABVX has a Quick Ratio of 0.77. This is a bad value and indicates that ABVX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.77, ABVX is doing worse than 80.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
ABVX.PA Yearly Current Assets VS Current LiabilitesABVX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ABVX.PA Growth Analysis

3.1 Past

  • ABVX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.09%.
EPS 1Y (TTM)-53.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.31%

3.2 Future

  • Based on estimates for the next years, ABVX will show a small growth in Earnings Per Share. The EPS will grow by 1.87% on average per year.
  • Based on estimates for the next years, ABVX will show a very strong growth in Revenue. The Revenue will grow by 180.54% on average per year.
EPS Next Y81.52%
EPS Next 2Y6.92%
EPS Next 3Y23.89%
EPS Next 5Y1.87%
Revenue Next Year-10.7%
Revenue Next 2Y514.77%
Revenue Next 3Y428.14%
Revenue Next 5Y180.54%

3.3 Evolution

ABVX.PA Yearly Revenue VS EstimatesABVX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
ABVX.PA Yearly EPS VS EstimatesABVX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. ABVX.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ABVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ABVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVX.PA Price Earnings VS Forward Price EarningsABVX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVX.PA Per share dataABVX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4

4.3 Compensation for Growth

  • ABVX's earnings are expected to grow with 23.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.92%
EPS Next 3Y23.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABVX.PA Dividend Analysis

5.1 Amount

  • ABVX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABVX.PA Fundamentals: All Metrics, Ratios and Statistics

ABIVAX SA

EPA:ABVX (4/24/2026, 7:00:00 PM)

96

-1.95 (-1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23
Earnings (Next)05-25
Inst Owners37.95%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.61B
Revenue(TTM)N/A
Net Income(TTM)-336.10M
Analysts85.71
Price Target132.35 (37.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.18%
PT rev (3m)11.61%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-10.89%
Revenue NY rev (3m)-14.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.28
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS0
BVpS-0.61
TBVpS-0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -280.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z 14.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
EPS Next Y81.52%
EPS Next 2Y6.92%
EPS Next 3Y23.89%
EPS Next 5Y1.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.31%
Revenue Next Year-10.7%
Revenue Next 2Y514.77%
Revenue Next 3Y428.14%
Revenue Next 5Y180.54%
EBIT growth 1Y-42.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.18%
EBIT Next 3Y69.97%
EBIT Next 5Y45.52%
FCF growth 1Y12.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.42%
OCF growth 3YN/A
OCF growth 5YN/A

ABIVAX SA / ABVX.PA Fundamental Analysis FAQ

What is the fundamental rating for ABVX stock?

ChartMill assigns a fundamental rating of 1 / 10 to ABVX.PA.


What is the valuation status of ABIVAX SA (ABVX.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to ABIVAX SA (ABVX.PA). This can be considered as Overvalued.


Can you provide the profitability details for ABIVAX SA?

ABIVAX SA (ABVX.PA) has a profitability rating of 0 / 10.


How financially healthy is ABIVAX SA?

The financial health rating of ABIVAX SA (ABVX.PA) is 2 / 10.


Can you provide the expected EPS growth for ABVX stock?

The Earnings per Share (EPS) of ABIVAX SA (ABVX.PA) is expected to grow by 81.52% in the next year.